- Home
- CNF vs NRXP Comparison
CNF vs NRXP Comparison
Compare CNF & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNF
- NRXP
- Stock Information
- Founded
- CNF 1999
- NRXP 2015
- Country
- CNF China
- NRXP United States
- Employees
- CNF N/A
- NRXP N/A
- Industry
- CNF Finance: Consumer Services
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- CNF Finance
- NRXP Health Care
- Exchange
- CNF Nasdaq
- NRXP Nasdaq
- Market Cap
- CNF 59.0M
- NRXP 51.3M
- IPO Year
- CNF 2018
- NRXP N/A
- Fundamental
- Price
- CNF $1.12
- NRXP $2.28
- Analyst Decision
- CNF
- NRXP Strong Buy
- Analyst Count
- CNF 0
- NRXP 3
- Target Price
- CNF N/A
- NRXP $31.67
- AVG Volume (30 Days)
- CNF 22.5K
- NRXP 464.9K
- Earning Date
- CNF 03-27-2025
- NRXP 03-27-2025
- Dividend Yield
- CNF N/A
- NRXP N/A
- EPS Growth
- CNF N/A
- NRXP N/A
- EPS
- CNF 0.24
- NRXP N/A
- Revenue
- CNF $109,788,152.00
- NRXP N/A
- Revenue This Year
- CNF N/A
- NRXP N/A
- Revenue Next Year
- CNF $13.09
- NRXP N/A
- P/E Ratio
- CNF $4.67
- NRXP N/A
- Revenue Growth
- CNF 12.99
- NRXP N/A
- 52 Week Low
- CNF $0.81
- NRXP $1.10
- 52 Week High
- CNF $2.84
- NRXP $7.33
- Technical
- Relative Strength Index (RSI)
- CNF 47.25
- NRXP 38.85
- Support Level
- CNF $1.07
- NRXP $2.80
- Resistance Level
- CNF $1.23
- NRXP $3.07
- Average True Range (ATR)
- CNF 0.09
- NRXP 0.29
- MACD
- CNF -0.02
- NRXP -0.10
- Stochastic Oscillator
- CNF 20.87
- NRXP 2.52
About CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.